Kyowa Kirin Australia general manager Simon Dawson says the company's "focus remains firmly on securing PBS reimbursement" of its CRYSVITA (burosumab) for the treatment of X-linked hypophosphataemia. …
Kyowa Kirin marks registration of XLH treatment but 'focused' on PBS
September 14, 2021 Latest NewsBioPharma
Latest Video
New Stories
-
Government moves on general co-pay as safety gets further out of reach
July 29, 2025 - - Latest News -
'For these families, genomics is not a luxury—it’s the only viable path'
July 29, 2025 - - Latest News -
Pharmac identifies the wider societal benefit of treatments for chronic conditions
July 28, 2025 - - Latest News -
Australian cell therapy company appoints experienced executive as CEO
July 28, 2025 - - Australian Biotech -
Alterity Therapeutics reports positive topline data from Phase 2 trial of ATH434
July 28, 2025 - - Australian Biotech -
Radiopharm Theranostics receives IND approval to initiate Phase 1 study
July 28, 2025 - - Australian Biotech -
Clarity successfully completes $203 million institutional placement
July 28, 2025 - - Australian Biotech